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Abstract:  The major immediate-early (IE) gene of human cytomegalovirus (CMV) is 
believed to have a decisive role in acute infection and its activity is an important indicator of 
viral reactivation from latency. Although a variety of gene products are expressed from this 
region, the 72-kDa IE1 and the 86-kDa IE2 nuclear phosphoproteins are the most abundant 
and important. Both proteins have long been recognized as promiscuous transcriptional 
regulators. More recently, a critical role of the IE1 and IE2 proteins in counteracting non-
adaptive host cell defense mechanisms has been revealed. In this review we will briefly 
summarize the available literature on IE1- and IE2-dependent mechanisms contributing to 
CMV evasion from intrinsic and innate immune responses. 
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1. Human Cytomegalovirus (CMV) Is a Significant Pathogen 
CMV, the prototype -herpesvirus, is the cause of a “silent pandemic” that continuously inflicts 
suffering upon people including immunocompromised patients as well as pregnant mothers and their 
unborn or prematurely newborn babies (reviewed in [1]). In the absence of an approved vaccine viral 
DNA polymerase inhibitors, including the nucleoside analogon ganciclovir, have provided major 
advances in CMV disease management. However, use of these drugs is limited by significant toxicity 
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and relatively modest effectiveness due to poor bioavailability and problems with viral drug resistance 
(reviewed in [2]). Furthermore, no drug has been licensed to treat congenital CMV infection, and 
recent trials with newly developed antivirals targeting CMV have not lived up to their expectations. 
Thus, it is still imperative to develop new anti-CMV strategies directed at appropriate viral molecular 
targets. 
2. The CMV Major Immediate-Early (IE) Proteins Are Multifunctional Key Regulators 
2.1. Structure and Importance of the Major IE Gene 
Figure 1. Structural organization and protein products of the CMV major IE locus. At the 
top of the diagram, the lengths and relative positions of exons 1 to 5 (the four coding exons 
are presented as black boxes and non-coding exon 1 as open box) and the location of the 
major IE promoter-enhancer (MIEP) are shown. Proteins are subdivided into the IE1 
(containing exon 4 sequences) and IE2 (containing exon 5 sequences) subfamilies. The 
predominant major IE protein species, which are the subject of this review, are highlighted 
in blue. It is uncertain whether the IE1 isoforms shown in gray are present in CMV-
infected cells [4]. All IE proteins are expressed from differentially spliced mRNAs, but 
exon 5 also encodes at least two different late proteins whose mRNAs are transcribed from 
internal promoters (LP). None of the minor IE1 and IE2 protein isoforms has been 
characterized with respect to activities in intrinsic or innate immune evasion.  
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Within the >230,000 base pair CMV DNA genome, the major IE gene is believed to have a decisive 
role in acute infection and reactivation from viral latency. Through differential splicing, 
polyadenylation and promoter usage this viral genomic region produces multiple mRNAs (reviewed in 
[3]). Although a variety of protein products expressed from these mRNAs have been identified [4-7] 
(Figure 1), the 72-kDa IE1 and the 86-kDa IE2 nuclear phosphoproteins are the most abundant and 
important. They share 85 amino-terminal
 amino acids corresponding to major IE exons 2 and
 3 but 
have distinct carboxy-terminal parts encoded by exon 4
 (IE1) or exon 5 (IE2) (Figure 1). While IE2 is 
absolutely indispensable for productive viral replication [8,9], IE1 is only conditionally essential. In 
fact, IE1-null viruses replicate efficiently in fibroblasts at a high multiplicity of infection (MOI). 
However, the absence of IE1 results in severely attenuated viral replication under low MOI conditions 
[10,11]. 
2.2. Functional Activities of the IE1 and IE2 Proteins 
IE2 is the principal transcriptional activator of the
  CMV early genes [8,9]. In addition, IE2 
negatively regulates viral gene expression including its own transcription (reviewed in [3,12]). IE1 
appears to synergize with IE2 to promote transcriptional activation of the viral early genes, at least 
after low MOI infection [10,13]. Moreover, both IE1 and IE2 have been shown to activate certain host 
cell promoters (e.g., [6,14-20]) (reviewed in [3,12]). More recently, it has also been demonstrated that 
the two major IE proteins can individually block induction of distinct sets of potentially antiviral host 
genes [21-25]. In IE1, this activity depends at least partially on interactions with human signal 
transducer and activator of transcription (STAT) proteins. Beyond that, transcriptional regulation by 
IE1 and IE2 appears to involve multiple interactions with basal and accessory cellular transcription 
factors (reviewed in [1,3,12]) including histone modifying enzymes [24,26-30]. The latter are 
important for IE1- and IE2-dependent regulation of core histone tail acetylation and/or methylation 
[26-28,31]. In addition to their effects on the covalent modification and function of chromatin-
associated proteins, IE1 and IE2 may also more directly act on DNA metabolism and structure. IE2 has 
been shown to block host cell DNA replication [32-34]. Furthermore, both major IE proteins seem to 
introduce mutations in cellular DNA [35], although the relevance of this observation remains to be 
determined. The chromatin-based activities of IE1 and IE2 are linked to their intranuclear localizations 
in ways that have not been fully elucidated. While IE2 binds sequence-specifically to DNA [36], IE1 
does not seem to interact with DNA directly. However, IE1 associates with (mitotic) host cell 
chromatin [37,38], presumably via protein-protein interaction. In addition, both IE1 and IE2 target to 
interchromatinic matrix-associated nuclear domain 10 (ND10) compartments of the cell nucleus. IE1 
disrupts these compartments most likely via interaction with the promyelocytic leukemia (PML) 
protein, the main structural organizer of ND10 [39-42]. 
Other activities associated with IE1 and IE2 expression concern effects on cell cycle progression 
and cell survival (reviewed in [43]). Ectopic IE1 can trigger a p53-dependent G1 growth arrest 
response [44], while it induces quiescent cells to enter S phase in p53-negative cells [45]. IE1 might 
stimulate S phase entry via interaction with the pocket protein p107 [46-48] and/or phosphorylation of 
p107, p130, and E2Fs through a reported kinase activity [49]. Similarly, transient IE2 expression may 
either promote cell cycle progression to the G1/S interface or growth arrest at G1/S or G2/M Viruses 2009, 1                                       
 
 
763
[33,44,50-52] (reviewed in [53]). IE2 may even induce premature cellular senescence [54]. At least 
some of the IE2-dependent effects on the cell cycle likely involve interactions with p53 and/or the 
retinoblastoma (Rb) tumor suppressor protein [55-59]. Finally, both IE1 and IE2 have been shown to 
counteract apoptotic cell death [60-65]. 
A comparative summary of activities that have been ascribed to the CMV IE1 and IE2 proteins is 
presented as Table 1. 
Table 1. Common and distinct activities of the CMV IE1 and IE2 proteins. 
Activities IE1 IE2  Selected  References 
CMV replication 
Requirement for viral replication at low MOI  +  +  [8-11] 
Requirement for viral replication at high MOI  –  +  [8-11] 
Cell cycle and apoptosis 
Inhibition of cell cycle progression  +  +  [33, 44,50-52] 
Induction of cell cycle progression  +  +  [33, 45,51,66] 
Inhibition of apoptosis  +  +  [60-65] 
Induction of senescence  –  +  [54] 
Nuclear structures 
ND10 targeting  +  +  [39,40,42] 
ND10 disruption  +  –  [39,40,42] 
Mitotic chromatin association  +  –  [37,38] 
DNA binding  –  +  [36] 
Histone modification 
Core histone tail acetylation  +  (+)  [26] 
Core histone tail methylation  –  +  [27,31] 
DNA metabolism 
Inhibition of cellular DNA replication  –  +  [32-34] 
Induction of mutations in cellular DNA  +  +  [35] 
Transcription
Activation of viral genes  +  +  reviewed in [1,3,12] 
Repression of viral genes  –  +  reviewed in [1,3,12] 
Activation of cellular genes  +  +  [6,14-20] 
Inhibition of cellular gene activation  +  +  [21-25] 
Other activities
Kinase activity  +  –  [49] 
+, positive; (+), likely positive; –, negative or unknown. Shading indicates activities most 
relevant to this review. 
 
2.3. IE1 and IE2 in Innate and Intrinsic Immunity 
The innate (in the broader sense) immune system of many organisms includes both inducible (innate 
in the stricter sense) and constitutive (intrinsic) mechanisms. Inducible innate mechanisms largely 
depend on pathogen-initiated cytokine production and signaling. Intrinsic responses like apoptosis, 
autophagy, and viral genome-directed repression mechanisms have only recently been recognized as 
an essential component of immunity which gives all cells the capacity to respond to infection. In the 
following paragraphs we will expand on the activities of CMV IE1 and IE2 that have established the 
two viral proteins as antagonists of innate and intrinsic antiviral host responses. Viruses 2009, 1                                       
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3. The CMV IE1 and IE2 Proteins Exhibit Antiapoptotic Potential 
3.1. Apoptosis Pathways in Antiviral Host Defense 
Apoptosis is a genetically regulated process of cell suicide resulting from activation of intrinsic or 
extrinsic death signaling pathways (reviewed in [67,68]). Intrinsic proapoptotic signals generated by 
diverse stresses such as growth factor withdrawal, DNA damage, or hypoxia trigger mitochondrial 
membrane permeabilization. Permeability transition is linked to mitochondrial dysfunction and the 
release of cytochrome c and other proapoptotic factors from the organelle’s intermembrane space into 
the cytosol. These factors eventually activate “initiator” cysteine aspartase (caspase) 9 as well as 
caspase-independent downstream mechanisms [67]. The control of mitochondrial apoptotic events is 
largely accomplished through the Bcl-2 family of proteins, which include both pro- (e.g., Bax) and 
antiapoptotic (e.g., Bcl-2) members (reviewed in [69]). The tumor suppressor protein p53, in turn, has 
a critical role in regulating the expression of Bax and other key proteins involved in (intrinsic) 
apoptosis (reviewed in [70]). The extrinsic signaling pathways that initiate apoptosis start with “death 
receptor” activation at the cell surface. For example, tumor necrosis factor (TNF)  or Fas ligand bind 
to TNF receptor 1 or Fas/CD95, respectively (reviewed in [71]). These interactions induce receptor 
oligomerisation, recruitment of cytoplasmic adapter proteins, and formation of a death-inducing 
signaling complex with initiator caspase-8. The complex subsequently triggers activation of caspase-8, 
which is negatively regulated by the FLICE inhibitory protein (FLIP). For most cell types, extrinsic 
signals are also amplified by crosstalk with the intrinsic mitochondrial pathway and caspase-9 
activation. Intrinsic and extrinsic pathways eventually converge on a downstream “execution phase”. 
Caspase-3 is considered to be the most important effector or “executioner” caspase and is activated by 
any of the initiator caspases. Executioner caspases cleave various protein substrates ultimately causing 
the biochemical and morphological hallmarks of apoptotic cells including chromatin fragmentation 
and cellular disintegration. 
Apoptosis typically occurs during development and as a homeostatic mechanism in normal cell 
turnover. However, the elimination of infected cells via apoptotic cell death is also considered one of 
the most primordial defense mechanisms against intracellular pathogens including viruses. Thus, 
disabling host cell apoptosis might represent an obligate step in the viral life cycle. Correspondingly, 
numerous viral proteins have been reported to modulate the apoptotic response of the host cell to 
infection (reviewed in [72]). 
3.2. Role of IE1 and IE2 in Apoptosis Inhibition 
Although it is now clear that cytomegaloviruses employ multiple strategies to delay cell death in 
infected cells (reviewed in [73]), the IE1 and IE2 proteins were the first CMV gene products reported 
to block apoptosis [60]. Following transient or stable expression in HeLa cells, IE1 and IE2 
individually inhibited induction of extrinsic apoptosis by short exposure to TNF- and cycloheximide 
or by infection with a proapoptotic mutant (E1B-19kDa-deficient) adenovirus. However, the viral 
proteins did not protect HeLa cells from TNF--or Fas-mediated apoptosis under more stringent 
experimental conditions [74] or when cell death was triggered by irradiation with ultraviolet (UV) 
light [60]. Subsequently, the anti-apoptotic effects of ectopic IE1 and/or IE2 expression have been Viruses 2009, 1                                       
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confirmed in other cancer cell lines and in primary cells [28,61-64,75]. However, the impact of the 
IE1- and IE2-associated pro-life activities on CMV infection remain unexplored. 
There is no evidence that IE1 or IE2 interfere with mitochondria-related apoptotic processes, and 
the two proteins do not alter the expression of Bcl-2 or Bax [60]. Instead, IE1 and IE2, expressed in 
concert or individually, inhibit apoptosis by activating the phosphatidylinositide 3’-OH kinase (PI3K) 
pro-survival pathway [61,62], which is also induced by CMV infection [62,76,77]. This has been 
demonstrated in the ts13 cell line, which carries a temperature-sensitive allele of the gene encoding 
TAFII250 and therefore undergoes apoptosis at the non-permissive temperature. Furthermore, 
combined expression of the viral IE proteins increased the activity of the serine/threonine kinase Akt 
(also known as protein kinase B), a major PI3K downstream target (reviewed in [78,79]). Akt 
promotes cell survival in part by targeting IB kinase, which phoshorylates IB resulting in nuclear 
localization of NFB and activation of NFB-responsive promoters of antiapoptotic genes. In fact, 
several cellular [15-17], viral [80-82] and artificial [62] promoters have been shown to be 
transcriptionally activated by CMV IE1 in an NFB-dependent fashion. However, IE2 may rather 
repress than stimulate transcription from NFB-regulated promoters [21,22,25,83]. On the other hand, 
IE2 appears to activate expression of cellular FLIP in CMV-infected retinal pigment epithelial cells 
and human retina tissue [65]. FLIP blocks the apoptotic pathway by interacting with caspase-8 at the 
death-inducing signaling complex. Notably, IE2-specific up-regulation of FLIP in CMV-infected 
retinal cells depends on PI3K [65]. 
In addition, mechanisms involving the tumor suppressor protein p53 have been proposed to account 
for the observed inhibitory effects of CMV IE2 on cellular apoptosis. IE2 binds to p53 and interferes 
with the tumor suppressor protein’s transcriptional activator function [55,56,84]. It was further 
demonstrated that IE2 can repress the acetylase activity of p300/cAMP response element binding 
protein binding protein (CBP) towards p53, rendering the tumor suppressor protein unable to execute 
UV-dependent apoptosis of colon cancer cells [28]. Moreover, expression of IE2, but not IE1, protects 
smooth muscle cells from p53-mediated apoptosis [63]. Rather than p53, IE1 targets the tumor 
suppressor protein PML [41], but the functional impact of this interaction on cell survival has not been 
evaluated. This potential link warrants future investigation since PML is known to affect PI3K 
signaling, p53 activity, and apoptosis (reviewed in [85,86]). 
In summary, it appears that each of the CMV major IE proteins can block extrinsic apoptosis 
pathways via activation of PI3K signaling, although no physical interaction partner (besides PML) of 
IE1 or IE2 has so far been identified in this pathway. Beyond that, additional mechanisms likely 
contribute to inhibition of apoptosis by the viral proteins that may involve IE2-p53 complex formation 
and other known or unidentified interactions. Despite the fact that the antiapoptotic potential of the 
two major IE proteins has clearly been established in several overexpression settings, its true relevance 
for viral infection and pathogenesis remains to be determined. 
4. The CMV IE1 Protein Counteracts ND10-Dependent Antiviral Responses 
4.1. Association of Parental Viral Genomes and IE Proteins with ND10 
A general feature of nuclear replicating DNA viruses including CMV is the preferential association 
of their parental genomes and prereplicative sites with functionally promiscuous interchromatin Viruses 2009, 1                                       
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protein complexes known as ND10 (reviewed in [87] and in the article by Tavalai and Stamminger in 
this issue). Viral genome deposition at ND10 is followed by targeting of the de novo synthesized IE1 
and IE2 proteins to these subnuclear complexes [42,88]. While IE1 usually colocalizes precisely with 
all nuclear ND10, IE2 was shown to switch between perfectly overlapping and juxtaposed locations 
relative to a subset of these structures [89]. In fact, it has been proposed that IE2 foci and ND10 
represent separate complexes that form independently during infection [89]. In any case, the spatial 
interplay between IE2 dots and ND10 can only be observed within a short time interval due to the 
action of the IE1 protein. IE1 disrupts ND10 during the early phase of CMV infection and upon 
ectopic expression [39,40,42]. The exact mechanism of IE1-dependent ND10 disruption remains 
unclear, although it likely involves binding to and de-SUMOylation of the PML protein [41,90,91]. 
4.2. IE1 as Antagonist of ND10-Related Intrinsic Defenses 
PML is a major constituent of ND10, and two main lines of evidence support the idea that this 
protein mediates an intrinsic immune response against CMV. First, the course of the CMV infectious 
cycle is significantly attenuated in cells overexpressing PML [92]. Secondly, short interfering RNA 
(siRNA)-mediated depletion of PML results in markedly increased IE gene expression and more 
efficient initiation of productive infection [93]. Importantly, PML knock-down efficiently compensates 
for IE1 in promoting replication of an IE1-deficient mutant virus [93]. This observation extends earlier 
findings suggesting a link between ND10 disruption and the activities of IE1 in transcriptional 
activation of viral early gene expression [92]. 
Interestingly, not only PML but also other ND10 components including death domain-associated 
protein (Daxx) and -thalassemia/mental retardation syndrome X-linked protein (ATRX) appear to be 
involved in an intrinsic antiviral response against CMV that limits viral gene expression [93-97]. 
Several of these ND10 proteins have been implicated in epigenetic processes (reviewed in [98]). For 
example, Daxx interacts with histones as well as histone deacetylases (HDACs) and forms part of a 
chromatin remodelling complex together with ATRX [99,100]. Therefore, it is tempting to speculate 
that ND10 proteins may contribute to formation of a repressive chromatin structure on newly infecting 
virus DNA. In fact, evidence for a “pre-IE” intrinsic antiviral response based on hypoacetylation and 
repressive methylation of core histones associated with CMV genomes has very recently been 
provided by Groves et al. [101]. In this context it is relevant to note that the CMV (and murine 
cytomegalovirus) IE1 protein is known to promote histone acetylation, at least in part by antagonizing 
HDAC activity [26,102]. It should also be mentioned that the CMV tegument protein pp71 interacts 
with Daxx and antagonizes Daxx-mediated histone deacetylation to activate the viral major IE 
promoter by targeting the cellular repressor protein for degradation [95,132-134]. Futhermore, pp71 
displaces ATRX from ND10 at pre-IE times post CMV infection [97]. These observations suggest that 
pp71 may contribute to relieving ND10-based intrinsic defenses even prior to IE gene expression. 
Nonetheless, it seems likely that counteracting intrinsic repression mediated by ND10 or at least 
one of its components (i.e., PML) is a key activity by which CMV IE1 facilitates productive viral 
replication at low viral input multiplicities (assumed to be the natural mode of infection). The IE1-
dependent effects on histone acetylation and ND10 integrity may both contribute, either individually 
or interdependently, to evasion from ND10-related antiviral defenses. Viruses 2009, 1                                       
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5. The CMV IE1 and IE2 Proteins Counteract Antiviral Cytokine Responses 
5.1. Cytokine-Based Innate Immunity Against Viral Infection  
Cytokines are secreted proteins which mediate fundamental
  processes in immune control and 
inflammation. Certain cytokines, such as TNF- and interferons (IFNs), produce intracellular signals 
that can cause apoptotic, cytostatic, or directly antiviral processes thereby limiting virus replication 
(reviewed in [103-105]). Particularly type I IFNs (primarily IFN- and multiple subtypes of IFN-) 
contribute critically to the induction of the innate immune response against most if not all viruses 
including CMV (reviewed in [103,104,106,107]). 
Expression of type I IFNs results from stimulation of pattern recognition receptors and is 
transcriptionally regulated through coordinated activation of latent (i.e., inactive) transcription factors 
including (among others) NFB and IFN regulatory factor 3 (IRF3). Following gene induction and 
protein secretion, type I IFNs bind to their cognate cell surface receptor, resulting in phosphorylation 
of tyrosine kinase 2 (Tyk2) and Janus kinase 1 (Jak1). The activated kinases subsequently 
phosphorylate the STAT1 and STAT2 proteins. This leads to heterodimerization of the STATs, 
association with IFN regulatory factor 9 (IRF9), and nuclear translocation of the trimeric complex 
(termed IFN-stimulated gene factor 3, ISGF3) (reviewed in [108]). Although this classical paradigm of 
Jak-STAT signal transduction has recently been challenged (reviewed in [109]), there is general 
agreement that ISGF3 ultimately binds sequence-specifically to promoters of numerous IFN-
stimulated genes (ISGs), resulting in their transcriptional activation. ISG products are the terminal IFN 
effector molecules many of which contribute to either inhibiting virus replication in infected cells or to 
establishing an “antiviral state” in uninfected cells. Examples of typical ISGs with antiviral activity 
include ISG15, MxA, PML, protein kinase R, and 2',5'-oligoadenylate synthetase (reviewed in 
[103,108]). Type I IFNs are also known to help activating natural killer (NK) cells and, although IFN- 
(type II IFN) plays a major role in promoting transition from innate to adaptive immune responses, 
IFN-/ are also important in this regard. For instance, type I IFNs promote the maturation of 
dendritic cells and sustain the proliferation of antigen-specific CD8
+ T cells. Moreover, these 
cytokines upregulate expression of class I major histocompatibility complex (MHC) molecules and 
other components of the antigen presenting machinery (reviewed in [103,110]). 
Despite their antiviral potential, CMV infection activates IRF3 and NFB inducing ISGs and type I 
IFNs (reviewed in [106,107]). However, infections performed in the absence of viral gene expression 
induce these genes more strongly [22, 111,112]. Yet even UV-inactivated virus did not seem to trigger 
full activation of the type I IFN pathway [111,113]. These observations suggested that CMV limits the 
type I IFN response through the actions of viral products introduced with the virus particle and 
synthesized during infection. Indeed, subsequent work has demonstrated that CMV interferes with 
multiple distinct steps in type I IFN synthesis, IFN-dependent signaling, and ISG effector function via 
both viral tegument and IE proteins [22-24,114-120]. Besides the IFN response, CMV also attenuates 
interleukin (IL) 1and TNF- proinflammatory signaling [121,122]. The CMV antagonists of 
proinflammatory cytokine (including type I IFN) induction and signal transduction include the IE1 and 
IE2 proteins. Viruses 2009, 1                                       
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Proinflammatory cytokines and type I IFNs are also known to induce the expression of several 
chemokines. Chemokines are cytokines with selective chemoattractant properties coordinating the 
homeostatic circulation of leukocytes as well as their movement to sites of inflammation or injury 
(reviewed in [123]). Chemokines are either divided into four subfamilies (C, CC, CXC, and CX3C), 
based on the arrangement of conserved amino-terminal cysteine residues, or into homeostatic and 
inflammatory proteins based on their patterns of expression and associated function. Homeostatic 
chemokines are constitutively produced and primarily involved in maintaining normal leukocyte 
trafficking. In contrast, expression of inflammatory chemokines (e.g., IL-8, MIP-1a, and RANTES) is 
typically induced in activated cells, and these proteins recruit leukocytes to inflamed tissues. In fact, 
chemokines attract the first wave of innate immune cells, including neutrophils, monocytes, and NK 
cells, all of which express inflammatory chemokine receptors (G protein-coupled receptors through 
which chemokines exert their function). Chemokines also recruit dendritic cells, which provide the 
link between innate and adaptive immunity, and stimulate the effector mechanisms of lymphocytes. 
Consequently, chemokines play a pivotal role in the resolution of virus infections (reviewed in [123]). 
As in the case of type I IFNs, CMV infection first activates the production of multiple chemokines, 
such as RANTES and MCP-1, in endothelial cells [124,125], fibroblasts [111,125,126], and monocytes 
[127]. However, CMV has also evolved multiple strategies to counteract chemokine-mediated immune 
responses, including sequestration by virus-encoded chemokine receptors [124,128,129] and direct 
suppression of chemokine production [124,130]. The latter process involves the viral IE2 protein. 
5.2. IE2-Mediated Inhibition of Cytokine Induction  
The CMV IE2 protein can efficiently block virus-induced expression of (inflammatory) chemokines 
including IL-8, MCP-2, MIG, MIP-1a, and RANTES [25]. Moreover, IE2 inhibits induction of the 
cytokines IFN-[22] and IL-6 [21,83] and of genes responsive to TNF- [21]. Since most of these 
genes carry NFB binding sites in their promoters, it was subsequently examined whether IE2 
interferes with the function of this transcription factor. In fact, IE2 appears to target intranuclear NFB 
to prevent or reverse virus- and TNF--induced sequence-specific DNA binding by this transcription 
factor. Interestingly, IE2 also blocks the activity of NFB when the activation domain of the cellular 
transcription factor is artificially tethered to a promoter [83]. This may indicate that IE2 inhibits 
NFB-dependent transcriptional activation at a step subsequent to promoter recruitment. 
5.3. IE1-Mediated Inhibition of Jak-STAT signaling 
The ability to inhibit potentially antiviral cytokine and chemokine induction does not seem to be 
shared between the CMV IE2 and IE1 proteins. In particular, CMV-induced IFN- gene epxression 
was not detectably counteracted by IE1 in various different settings [22-24]. However, IE1 has been 
shown to antagonize the type I IFN response at a step downstream of IFN production and secretion by 
interfering with Jak-STAT signaling. 
IE1 does not detectably interfere with the expression, stability, phosphorylation, or nuclear 
translocation of the STAT1 and STAT2 proteins. However, IE1 forms stable complexes with both 
STATs inside the nuclei of transfected and CMV-infected cells [23,24]. Moreover, the viral protein 
can redirect STAT2 (and STAT1) to nuclear matrix-associated (ND10) and chromatin compartments. Viruses 2009, 1                                       
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Similar to what has been described for IE2 regarding NFB targeting, IE1 precludes sequence-specific 
promoter binding by all three components (STAT1, STAT2, and IRF9) of ISGF3 [23,24]. However, 
STAT2 appears to be the viral protein’s primary target in the trimeric complex (S. Krauss, S. Meinel, 
I. Tschertner, C. Paulus, and M. Nevels, unpublished results). Interestingly, IE1-STAT2 complex 
formation appears to be negatively regulated by SUMOylation of the viral binding partner [24]. In 
accordance with reduced ISGF3 DNA binding, induction of ISGs including MxA, ISG54, and 
CXCL10 by CMV infection (or exogenous IFN treatment) is substantially dampened in the presence of 
IE1 [23,24]. Through STAT2 interaction the viral protein ultimately confers a substantial degree of 
protection against the antiviral effects of IFN- and IFN- upon CMV [23,24,131]. However, IE1 
counteracts the antiviral type I IFN response and promotes viral replication by at least two distinct 
mechanisms, one depending on sequestration of STAT2 and the other one likely involving ND10 
interaction [131] (Figure 2). 
Figure 2. Model of IE1 activities in inhibition of IFN-mediated antiviral gene expression 
and induction of viral gene expression. The predicted structural organization of CMV IE1, 
comprising a central globular domain and natively unstructured regions at the protein 
termini [131], is depicted at the top of the diagram. IE1 is proposed to antagonize the type I 
IFN-mediated antiviral host cell response by at least two distinct mechanisms. The first 
mechanism depends on binding of IFN-activatable STAT2 to the carboxy-terminal IE1 
domain resulting in inhibition of ISGF3-mediated anti-viral gene induction. The second 
mechanism is independent of IE1-STAT2 complex formation and may involve a 
previously described interaction with the IFN-inducible PML protein resulting in 
disruption of ND10, which has been mapped to central parts of the viral protein. Impaired 
PML function and ND10 integrity have both been linked to derepression of viral gene 
expression. In addition, ND10 may be involved in regulation of antiviral gene expression. 
Note that IE1 has also been proposed to activate viral gene expression more directly via 
interaction with cellular transcription factors and at least one HDAC. Black symbols 
represent experimentally verified connections, and gray symbols indicate hypothetical 
links. 
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6. Conclusions 
The innate host cell response to viral infection is in large parts characterized by the induction of 
cytokines and inflammatory chemokines. In addition, constitutively active intrinsic antiviral defense 
mechanisms (e.g., apoptosis and chromatin-based repression) ubiquitously exist. The IE1 and IE2 
proteins are among the first de novo synthesized proteins following primary CMV infection or viral 
reactivation. It emerges that a principal task of IE1 and IE2 is to counteract intrinsic and innate host 
responses that would otherwise terminate the viral life cycle in its very beginnings. In particular, IE1 
antagonizes apoptosis, ND10-related transcription silencing, and type I IFN signaling. Likewise, IE2 
inhibits apoptosis and inflammatory cytokine/chemokine induction. In comparison to the long 
recognized direct effects of IE1 and IE2 on viral transcription, their rather recently discovered immune 
evasion activities may turn out to be equally important to assure viral replicative success. 
Consequently, the interactions of IE1/IE2 with host cell innate and intrinsic defense pathways may 
provide new opportunities for antiviral intervention. 
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